Produktinformation
- 5,11-Dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-6H-pyrimido[4,5-b][1,4] benzodiazepin-6-one
LRRK2-IN-1 is a kinase inhibitor that targets the LRRK2 protein. It specifically inhibits the kinase domain of this protein, which has been implicated in the development and progression of cancer. LRRK2-IN-1 is a monoclonal antibody that binds to this domain and dephosphorylates it, leading to apoptosis in cancer cells. This drug also has pharmacokinetic properties that are suitable for administration by injection or infusion. The binding of LRRK2-IN-1 to its target leads to the disruption of mitochondrial membrane potential, which may be one of the mechanisms by which it causes cancer cell death. It also has anticancer activity against pancreatic cancer cells and other cancers with high levels of LRRK2 expression such as breast, lung, and ovarian cancers. In addition, LRRK2-IN-1 has been shown to inhibit cancer stem cells in colon and prostate cancers.
